keyword
MENU ▼
Read by QxMD icon Read
search

Recurrent ovarian

keyword
https://www.readbyqxmd.com/read/29673836/effects-of-lifestyle-modification-on-cancer-recurrence-overall-survival-and-quality-of-life-in-gynaecological-cancer-survivors-a-systematic-review-and-meta-analysis
#1
REVIEW
Ladan Yeganeh, Cheryce Harrison, Amanda J Vincent, Helena Teede, Jacqueline A Boyle
The benefits of lifestyle interventions for women who have survived gynaecological cancer (GC) remain unclear. This systematic review aimed to determine the effect of lifestyle interventions on cancer recurrence, overall survival and quality of life (QoL) in women with GC. We searched Medline, Embase, PsycINFO and EBM Reviews from June to July 2016 to identify relevant literature. We included randomized controlled trials in which a lifestyle intervention (diet, weight loss, physical activity and/or behavioural interventions) were compared with a control condition (usual care, placebo or other lifestyle interventions) in women who had survived endometrial or ovarian cancer...
May 2018: Maturitas
https://www.readbyqxmd.com/read/29673667/the-role-of-preoperative-serum-cancer-antigen-125-in-malignant-ovarian-germ-cell-tumors
#2
Ju-Hyun Kim, Jeong-Yeol Park, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
OBJECTIVE: To determine the role of preoperative serum cancer antigen 125 (CA 125) in malignant ovarian germ cell tumors (MOGCTs). MATERIALS AND METHODS: Using information from medical databases of Asan Medical Center (Seoul, Korea), we investigated 161 patients with histologically diagnosed MOGCTs and whose preoperative serum CA 125 had been checked. We determined the optimal cutoff value of CA 125 as > 249.5 U/mL in MOGCTs using a receiver operating characteristic curve...
April 2018: Taiwanese Journal of Obstetrics & Gynecology
https://www.readbyqxmd.com/read/29673382/risk-of-synchronous-endometrial-disorders-in-women-with-endometrioid-borderline-tumors-of-the-ovary
#3
Shuang-Zheng Jia, Jun-Ji Zhang, Jun-Jun Yang, Yang Xiang, Zhiyong Liang, Jin-Hua Leng
BACKGROUND: Synchronous endometrial disorders have been poorly studied in women with endometrioid borderline ovarian tumors (EBOT). The aims of this study were to investigate the risk of endometrial disorders among women with EBOT and associated factors, as well as their oncological and fertility outcomes. RESULTS: This retrospective study included 33 women with EBOT. Their mean age was 41.9 years, and endometria were evaluated in 25 of these patients. The prevalence of synchronous endometrial disorders was 52...
April 19, 2018: Journal of Ovarian Research
https://www.readbyqxmd.com/read/29673336/ab0-blood-groups-and-rhesus-factor-expression-as-prognostic-parameters-in-patients-with-epithelial-ovarian-cancer-a-retrospective-multi-centre-study
#4
Veronika Seebacher, Stephan Polterauer, Alexander Reinthaller, Heinz Koelbl, Regina Achleitner, Astrid Berger, Nicole Concin
BACKGROUND: AB0 blood groups and Rhesus factor expression have been associated with carcinogenesis, response to treatment and tumor progression in several malignancies. The aim of the present study was to test the hypothesis that AB0 blood groups and Rhesus factor expression are associated with clinical outcome in patients with epithelial ovarian cancer (EOC). METHODS: AB0 blood groups and Rhesus factor expression were evaluated in a retrospective multicenter study including 518 patients with EOC...
April 19, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29672168/rucaparib-a-new-treatment-option-for-ovarian-cancer
#5
Ilaria Sabatucci, Giuseppa Maltese, Stefano Lepori, Elisa Tripodi, Giorgio Bogani, Domenica Lorusso
Approximately 50% of high-grade serous ovarian cancers present a deficiency in the pathways involved in homologous recombination (HR). PARP inhibitors prevent single-strand DNA damage repair and determine a progression of the defect towards double-strand breaks, which results in a process known as 'synthetic lethality'. Areas covered: In this review, the authors discuss the efficacy and toxicity of rucaparib either as a single agent or as a maintenance treatment for ovarian cancer. This includes the NGS Foundation Medicine evaluation of the role of this drug in the treatment algorithm of ovarian cancer...
April 19, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29670374/multiline-treatment-combining-apatinib-with-toptecan-for-platinum-resistant-recurrent-ovarian-cancer-patients-a-report-of-three-cases
#6
Yuan Cheng, Juan Zhang, Haiyun Geng, Shukui Qin, Haiqing Hua
The aim of this study was to observe the efficacy and safety of apatinib combined with toptecan therapy in the multiline treatment of platinum-resistant recurrent ovarian cancer patients. The clinical records of three patients with platinum-resistant recurrent ovarian cancer treated with apatinib combined with toptecan therapy were analyzed and followed up for 3 months, and the related literatures were reviewed. The three patients achieved partial response and the tumor marker CA125 levels decreased significantly as an outcome of the treatment...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29664842/incidental-thoracic-findings-on-routine-computed-tomography-in-epithelial-ovarian-cancer
#7
Bobby D OʼLeary, Teresa Treacy, Tony Geoghegan, Tom A Walsh, William D Boyd, Donal J Brennan
INTRODUCTION: Multidetector computed tomography (MDCT) is routinely used in the surveillance of epithelial ovarian cancer. The aim of this study was to determine the incidence of thoracic findings on routine MDCT surveillance imaging in patients with ovarian carcinoma. MATERIALS AND METHODS: Retrospective evaluation of 100 MDCT studies of patients with a diagnosis of epithelial ovarian cancer was performed at a university teaching hospital. The cross-sectional studies were reviewed by a consultant radiologist with subspeciality training in cross-sectional imaging...
April 16, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29664840/malignant-ascites-validation-of-a-novel-ascites-symptom-mini-scale-for-use-in-patients-with-ovarian-cancer
#8
Ram Eitan, Oded Raban, Daliah Tsoref, Ariella Jakobson-Setton, Gad Sabah, Lina Salman, Effi Yeoshua, Avi Ben-Haroush
BACKGROUND: Ascites is a common finding in patients with ovarian cancer. Paracentesis is a relatively simple, safe, and effective procedure for draining fluid from the peritoneum, but valid quality-of-life tools are needed to determine its subjective value for alleviating symptoms and improving patient quality of life. The objective of this study was to prospectively evaluate the performance of a novel Ascites Symptom Mini-Scale (ASmS) and compare it with a previously available questionnaire...
April 16, 2018: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/29662660/clinical-outcomes-of-women-with-ovarian-metastases-of-colorectal-cancer-treated-with-oophorectomy-with-respect-to-their-somatic-mutation-profiles
#9
Yoshiko Mori, Akihiro Nyuya, Kazuya Yasui, Toshiaki Toshima, Takashi Kawai, Fumitaka Taniguchi, Keisuke Kimura, Ryo Inada, Masahiko Nishizaki, Junko Haraga, Keiichiro Nakamura, Yuzo Umeda, Hiroyuki Kishimoto, Toshiyoshi Fujiwara, Yosuke Katata, Yoshiyuki Yamaguchi, Takeshi Nagasaka
We clarified the clinical prevalence of ovarian metastases from colorectal cancers (CRCs) in 296 female patients with CRC and evaluated clinical outcomes with relation to their mutational profiles, such as BRAF/KRAS mutation and microsatellite instability (MSI) status. The female CRCs were categorised into three subsets: CRCs with ovarian metastases [6.4% ( n = 19), 5-year overall survival (OS) = 24.7%], CRCs with extra-ovarian metastases only [32.4% ( n = 96), 5-year OS = 34.5%] and CRCs without any recurrence or metastasis [61...
March 27, 2018: Oncotarget
https://www.readbyqxmd.com/read/29662608/wt1-p53-and-p16-expression-in-the-diagnosis-of-low-and-high-grade-serous-ovarian-carcinomas-and-their-relation-to-prognosis
#10
Luis Felipe Sallum, Liliana Andrade, Susana Ramalho, Amanda Canato Ferracini, Rodrigo de Andrade Natal, Angelo Borsarelli Carvalho Brito, Luis Otávio Sarian, Sophie Derchain
Objective: To evaluate the diagnostic and prognostic value of the immunohistochemical expression of WT1, p53 and p16 in low- (LGSOCs) and high-grade serous ovarian carcinomas (HGSOCs). Results: HGSOC had a significantly higher proportion of advanced stage disease, higher CA125 levels, higher proportion of post-surgery residual disease and higher recurrence or disease progression. WT1 was expressed in 71.4% of LGSOCs and in 57.1% of HGSOCs ( p = 0.32). Focal and/or complete absence of p53 expression with negative p16 expression was found in 90...
March 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29661166/high-ox40-expression-in-recurrent-ovarian-carcinoma-is-indicative-for-response-to-repeated-chemotherapy
#11
Michaela Ramser, Simone Eichelberger, Silvio Däster, Benjamin Weixler, Marko Kraljević, Robert Mechera, Athanasios Tampakis, Tarik Delko, Uwe Güth, Sylvia Stadlmann, Luigi Terracciano, Raoul A Droeser, Gad Singer
BACKGROUND: Ovarian carcinoma (OC) is the fifth most common female cancer and mostly diagnosed at an advanced stage. Surgical debulking is usually followed by adjuvant platinum-based chemotherapy. Only few biomarkers are known to be related to chemosensitivity. OX40 is a TNF receptor member and expressed on activated CD4+ and CD8+ T cells. It is known that OX40 signaling promotes survival and responds to various immune cells of the innate and adaptive immune system. Therefore we investigated the indicative value of OX40 expression for recurrence and survival in OC...
April 16, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29661159/active-dna-end-processing-in-micronuclei-of-ovarian-cancer-cells
#12
Zizhi Tang, Juan Yang, Xin Wang, Ming Zeng, Jing Wang, Ao Wang, Mingcai Zhao, Liandi Guo, Cong Liu, Dehua Li, Jie Chen
BACKGROUND: Ovarian cancer is one of the most deadly gynecological malignancies and inclined to recurrence and drug resistance. Previous studies showed that the tumorigenesis of ovarian cancers and their major histotypes are associated with genomic instability caused by defined sets of pathogenic mutations. In contrast, the mechanism that influences the development of drug resistance and disease recurrence is not well elucidated. Solid tumors are prone to chromosomal instability (CIN) and micronuclei formation (MN)...
April 16, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29658435/combined-immunotherapy-ok-432-il-2-with-chemotherapy-decrease-the-recurrence-rate-in-advanced-ovarian-cancer
#13
Yi-Lun Wang, Hsiu-Huei Peng, Sheng-Yuan Su, Cheng-Tao Lin
OBJECTIVE: In advanced ovarian cancer, traditional therapy included debulking surgery and postoperative chemotherapy. We proposed immunochemotherapy (IMCT) combined with picibanil (OK-432), interleukin-2 (IL-2), and traditional platinum- and taxol-based chemotherapy as a better treatment option for advanced ovarian cancer. METHODS: We retrospectively reviewed the medical records of 51 patients with advanced ovarian cancer between 2007 and 2015 at Chang Gung Memorial Hospital Linkou Medical Center, including 26 patients who were treated with OK-432, IL-2, and platinum- and taxol-based chemotherapy (IMCT group) after debulking surgery; another 25 were treated with traditional platinum- and taxol-based chemotherapy (traditional chemotherapy group) after debulking surgery...
January 1, 2018: Reproductive Sciences
https://www.readbyqxmd.com/read/29656069/-microscopic-peritoneal-metastases-of-epithelial-ovarian-cancers-clinical-relevance-diagnostic-and-therapeutic-tools
#14
Y Kerbage, G Canlorbe, J P Estevez, A Grabarz, S Mordon, C Uzan, P Collinet, H Azaïs
Understanding the biology and progression mechanisms of peritoneal metastases in ovarian epithelial cancers (EOC) is important because peritoneal carcinomatosis is present or will occur during surveillance of a majority of patients. Despite the clinical remission achieved after complete macroscopic cytoreductive surgery and platinum-based chemotherapy, 60% of patients will develop peritoneal recurrence. This suggests that microscopic lesions, which are not eradicated by surgery may be present and may participate in the mechanisms leading to peritoneal recurrence...
April 11, 2018: Gynecologie, Obstetrique, Fertilite & Senologie
https://www.readbyqxmd.com/read/29651788/sphincter-preserving-surgery-for-recurrent-pelvic-malignancy-using-a-hybrid-procedure-of-open-laparotomy-and-transanal-endoscopic-approach
#15
Seiji Ishiguro, Shunichiro Komatsu, Kenichi Komaya, Takuya Saito, Takashi Arikawa, Kenichiro Kaneko, Tsuyoshi Sano
BACKGROUND: Surgery for the treatment of recurrent pelvic malignancy is challenging. Sphincter-preserving surgery (SPS) has been applied in limited cases. Transanal endoscopic approach (TEA) has been used for primary rectal cancer, predominantly for hybrid transabdominal-transanal total mesorectal excision. Here, we describe the use of TEA as a hybrid approach in a case of recurrent ovarian cancer. CASE PRESENTATION: A 59-year-old woman had recurrence of serous ovarian adenocarcinoma in the vaginal stump, near the site of anastomosis from a rectal resection 18 months previously...
April 12, 2018: Surgical Case Reports
https://www.readbyqxmd.com/read/29650751/fda-approval-summary-niraparib-for-the-maintenance-treatment-of-patients-with-recurrent-ovarian-cancer-in-response-to-platinum-based-chemotherapy
#16
Gwynn Ison, Lynn J Howie, Laleh Amiri-Kordestani, Lijun Zhang, Shenghui Tang, Rajeshwari Sridhara, Vadryn Pierre, Rosane Charlab, Anuradha Ramamoorthy, Pengfei Song, Fang Li, Jingyu Yu, Wimolnut Manheng, Todd R Palmby, Soma Ghosh, Hisani N Horne, Eunice Y Lee, Reena Philip, Kaushalkumar Dave, Xiao Hong Chen, Sharon L Kelly, Kumar G Janoria, Anamitro Banerjee, Okponanabofa Eradiri, Jeannette Dinin, Kirsten B Goldberg, William F Pierce, Amna Ibrahim, Paul G Kluetz, Gideon M Blumenthal, Julia A Beaver, Richard Pazdur
The Food and Drug Administration approved niraparib, a poly ADP ribose polymerase (PARP) inhibitor, on March 27, 2017, for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy. Approval was based on data from the NOVA trial comparing niraparib with placebo in two independent cohorts, based on germline BRCA mutation status (gBRCAm vs. non-gBRCAm). Progression-free survival (PFS) in each cohort was the primary endpoint...
April 12, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29644766/fear-of-recurrence-among-older-breast-ovarian-endometrial-and-colorectal-cancer-survivors-findings-from-the-whi-lilac-study
#17
Jessica L Krok-Schoen, Michelle J Naughton, Brittany M Bernardo, Gregory S Young, Electra D Paskett
OBJECTIVE: To examine the prevalence of and factors associated with fear of recurrence (FCR) following treatment for breast, ovarian, endometrial, and colorectal cancer among older women. METHODS: Participants were enrolled in the Women's Health Initiative WHI Life and Longevity After Cancer (LILAC) study. Descriptive statistics and multivariate logistic regression models were used to assess the association of demographic, clinical, and quality of life variables with survivors' FCR, dichotomized as <14 (low) or ≥14 (high) using the Cancer Worry Scale...
April 12, 2018: Psycho-oncology
https://www.readbyqxmd.com/read/29644491/update-on-parp-inhibitors-in-breast-cancer
#18
REVIEW
Alexandra S Zimmer, Mitchell Gillard, Stanley Lipkowitz, Jung-Min Lee
The single agent activity of PARP inhibitors (PARPi) in germline BRCA mutated (gBRCAm) breast and ovarian cancer suggests untapped potential for this new class of drug in breast cancer. The US Food and Drug Administration has approved three PARPi (olaparib, rucaparib, and niraparib) so far to treat certain ovarian cancers, including those with gBRCAm and olaparib for treatment of gBRCAm breast cancers. Several PARPi are now under clinical development for breast cancer in the various treatment settings. Recently, two phase III trials of olaparib (OlympiaD) and talazoparib (EMBRACA) demonstrated 3-month progression-free survival improvement with PARPi compared to physician's choice single agent chemotherapy in metastatic gBRCAm breast cancer...
April 11, 2018: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29644333/risk-of-transplanting-malignant-cells-in-cryopreserved-ovarian-tissue
#19
Marie-Madeleine Dolmans, Rossella Masciangelo
Improvements in cancer treatments have increased the chances of survival of young cancer patients, but have given rise to other issues, like premature ovarian insufficiency and infertility. Preservation and subsequent restoration of ovarian function in these patients is now possible thanks to ovarian tissue cryopreservation and transplantation. However, safety concerns about the possible presence of cancerous cells in the tissue to be cryopreserved must be addressed. Indeed, reimplantation of malignant cell-contaminated ovarian tissue could potentially lead to recurrence of the primary disease...
April 11, 2018: Minerva Ginecologica
https://www.readbyqxmd.com/read/29644331/from-isolation-of-human-ovarian-follicles-to-the-artificial-ovary-tips-and-tricks
#20
Maria C Chiti, Jacques Donnez, Christiani Andrade Amorim, Marie-Madeleine Dolmans
Cryopreservation and transplantation of ovarian tissue has proved to restore both endocrine and reproductive functions in cancer patients. However women with a high risk of ovarian involvement cannot undergo ovarian tissue transplantation due to possible recurrence of the disease. Therefore, different teams worldwide are now working on the development of experimental strategies, like the transplantable artificial ovary (TAO), with the noble goal to offer to these patients hope for future conception. This article discusses some essential points for the creation of a TAO and reviews the latest progress made...
April 11, 2018: Minerva Ginecologica
keyword
keyword
103066
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"